Maxwell Plus joins fight against Alzheimer’s Disease

We were proud and excited yesterday to be included in the current round of Federal Government’s Cooperative Research Centre Projects funding in a new collaboration with I-MED, CSIRO and Austin Health.

In the $4.8m project, $1.1m funding was awarded to us to lead the joint collaboration to commercialise an AI platform to aid the detection and diagnosis of Alzheimer’s disease and other neurodegenerative conditions, allowing us to expand our Maxwell Plus Cloud reporting platform to a new cohort of clinicians and patients.

Originally developed by scientists at CSIRO’s Australian e-Health Research Centre, the CapAIBL brain image analysis tool enables automated and more accurate measurements of glucose, amyloid and tau in MRI and PET brain imaging — measurements which are key in assessing and diagnosing Alzheimer’s Disease.

Building on the work of CSIRO, we will apply state-of-the-art AI technology to CapAIBL to further analyse brain MRI scans helping clinicians to increase productivity, reduce misdiagnosis and improve doctor-patient communication.

More importantly, with 25,416 currently living with the disease and 250 being diagnosed each day, patients suffering from neurodegeneration will have access to cost effective and more accurate diagnosis.

We were proud that we were acknowledged as leading the future of health and look forward to commencing work with our partners to develop a new and exciting way to help people in Australia and beyond.